Literature DB >> 20010520

The false discovery rate: a key concept in large-scale genetic studies.

James J Chen1, Paula K Roberson, Michael J Schell.   

Abstract

BACKGROUND: In experimental research, a statistical test is often used for making decisions on a null hypothesis such as that the means of gene expression in the normal and tumor groups are equal. Typically, a test statistic and its corresponding P value are calculated to measure the extent of the difference between the two groups. The null hypothesis is rejected and a discovery is declared when the P value is less than a prespecified significance level. When more than one test is conducted, use of a significance level intended for use by a single test typically leads to a large chance of false-positive findings.
METHODS: This paper presents an overview of the multiple testing framework and describes the false discovery rate (FDR) approach to determining the significance cutoff when a large number of tests are conducted.
RESULTS: The FDR is the expected proportion of the null hypotheses that are falsely rejected divided by the total number of rejections. An FDR-controlling procedure is described and illustrated with a numerical example.
CONCLUSIONS: In multiple testing, a classical "family-wise error rate" (FWE) approach is commonly used when the number of tests is small. When a study involves a large number of tests, the FDR error measure is a more useful approach to determining a significance cutoff, as the FWE approach is too stringent. The FDR approach allows more claims of significant differences to be made, provided the investigator is willing to accept a small fraction of false-positive findings.

Entities:  

Mesh:

Year:  2010        PMID: 20010520     DOI: 10.1177/107327481001700108

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  18 in total

1.  A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort.

Authors:  P M Bet; E C Verbeek; Y Milaneschi; D B M Straver; T Uithuisje; M R Bevova; J G Hugtenburg; P Heutink; B W J H Penninx; W J G Hoogendijk
Journal:  Pharmacogenomics J       Date:  2015-05-19       Impact factor: 3.550

2.  Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.

Authors:  Litaty Céphanoée Mbatchi; Jacques Robert; Marc Ychou; Jean-Christophe Boyer; Maguy Del Rio; Matthieu Gassiot; Fabienne Thomas; Nicole Tubiana; Alexandre Evrard
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 3.  Study designs and statistical analyses for biomarker research.

Authors:  Masahiko Gosho; Kengo Nagashima; Yasunori Sato
Journal:  Sensors (Basel)       Date:  2012-06-29       Impact factor: 3.576

4.  Transcriptome wide annotation of eukaryotic RNase III reactivity and degradation signals.

Authors:  Jules Gagnon; Mathieu Lavoie; Mathieu Catala; Francis Malenfant; Sherif Abou Elela
Journal:  PLoS Genet       Date:  2015-02-13       Impact factor: 5.917

5.  Controlling false positive rates in research and its clinical implications.

Authors:  Rafael Simas; Felipe Maestri; David Normando
Journal:  Dental Press J Orthod       Date:  2014 May-Jun

6.  Revealing Alzheimer's disease genes spectrum in the whole-genome by machine learning.

Authors:  Xiaoyan Huang; Hankui Liu; Xinming Li; Liping Guan; Jiankang Li; Laurent Christian Asker M Tellier; Huanming Yang; Jian Wang; Jianguo Zhang
Journal:  BMC Neurol       Date:  2018-01-10       Impact factor: 2.474

7.  Phenome-wide association study using research participants' self-reported data provides insight into the Th17 and IL-17 pathway.

Authors:  Margaret G Ehm; Jennifer L Aponte; Mathias N Chiano; Laura M Yerges-Armstrong; Toby Johnson; Jonathan N Barker; Suzanne F Cook; Akanksha Gupta; David A Hinds; Li Li; Matthew R Nelson; Michael A Simpson; Chao Tian; Linda C McCarthy; Deepak K Rajpal; Dawn M Waterworth
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

8.  Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease.

Authors:  Christiane Reitz; Giuseppe Tosto; Richard Mayeux; Jose A Luchsinger
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

9.  Analysis of Prostate Cancer Susceptibility Variants in South African Men: Replicating Associations on Chromosomes 8q24 and 10q11.

Authors:  Pedro Fernandez; Muneeb Salie; Danielle du Toit; Andre van der Merwe
Journal:  Prostate Cancer       Date:  2015-08-12

10.  Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Pauline Bus; Christine Kestens; Fiebo Jan Willem Ten Kate; Wilbert Peters; Joost Paulus Hubertus Drenth; Jeanine Merel Leonoor Roodhart; Peter Derk Siersema; Jantine Wilhelmina Paula Maria van Baal
Journal:  J Gastroenterol       Date:  2015-11-19       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.